BioInvent International AB
STO:BINV
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.3
41.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| SE |
B
|
BioInvent International AB
STO:BINV
|
1.9B SEK |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
385.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.7B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.5B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.8B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
48.8B USD |
Loading...
|
Market Distribution
| Min | -2 025 693.8% |
| 30th Percentile | -1.8% |
| Median | 6% |
| 70th Percentile | 12.5% |
| Max | 10 459.2% |
Other Profitability Ratios
BioInvent International AB
Glance View
BioInvent International AB engages in the research and development of novel and immuno-modulatory antibodies for the treatment of cancer. The company is headquartered in Lund, Skane and currently employs 84 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for BioInvent International AB is -142.2%, which is above its 3-year median of -520.1%.
Over the last 3 years, BioInvent International AB’s Operating Margin has decreased from -16.3% to -142.2%. During this period, it reached a low of -1 179.3% on Sep 30, 2024 and a high of -15.5% on Dec 31, 2022.